145 related articles for article (PubMed ID: 19761819)
1. Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.
Sunkara G; Ayalasomayajula SP; DeRuiter J; Kompella UB
Brain Res Bull; 2010 Feb; 81(2-3):327-32. PubMed ID: 19761819
[TBL] [Abstract][Full Text] [Related]
2. Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor.
Sunkara G; Ayalasomayajula SP; Rao CS; Vennerstrom JL; DeRuiter J; Kompella UB
J Pharm Pharmacol; 2004 Mar; 56(3):351-8. PubMed ID: 15025860
[TBL] [Abstract][Full Text] [Related]
3. In-vitro hydrolysis, permeability, and ocular uptake of prodrugs of N-[4-(benzoylamino)phenylsulfonyl]glycine, a novel aldose reductase inhibitor.
Sunkara G; Deruiter J; Clark CR; Kompella UB
J Pharm Pharmacol; 2000 Sep; 52(9):1113-22. PubMed ID: 11045892
[TBL] [Abstract][Full Text] [Related]
4. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications.
Aukunuru JV; Sunkara G; Ayalasomayajula SP; DeRuiter J; Clark RC; Kompella UB
Pharm Res; 2002 Mar; 19(3):278-85. PubMed ID: 11934234
[TBL] [Abstract][Full Text] [Related]
5. The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integrated in vivo microdialysis study in the rat.
Donovan MD; O'Brien FE; Boylan GB; Cryan JF; Griffin BT
J Pharm Pharmacol; 2015 Apr; 67(4):501-10. PubMed ID: 25490899
[TBL] [Abstract][Full Text] [Related]
6. Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor.
Aukunuru JV; Sunkara G; Bandi N; Thoreson WB; Kompella UB
Pharm Res; 2001 May; 18(5):565-72. PubMed ID: 11465409
[TBL] [Abstract][Full Text] [Related]
7. Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration.
Amrite AC; Edelhauser HF; Singh SR; Kompella UB
Mol Vis; 2008 Jan; 14():150-60. PubMed ID: 18334929
[TBL] [Abstract][Full Text] [Related]
8. Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine.
Hagos FT; Daood MJ; Ocque JA; Nolin TD; Bayir H; Poloyac SM; Kochanek PM; Clark RS; Empey PE
Xenobiotica; 2017 Apr; 47(4):346-353. PubMed ID: 27278858
[TBL] [Abstract][Full Text] [Related]
9. Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator.
Weiss HM; Langenickel T; Cain M; Kulkarni S; Shah B; Vemula J; Rahmanzadeh G; Poller B
Drug Metab Dispos; 2021 May; 49(5):389-394. PubMed ID: 33632715
[TBL] [Abstract][Full Text] [Related]
10. The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide.
Töllner K; Brandt C; Römermann K; Löscher W
Eur J Pharmacol; 2015 Jan; 746():167-73. PubMed ID: 25449033
[TBL] [Abstract][Full Text] [Related]
11. Monocarboxylate transport inhibition alters retinal function and cellular amino acid levels.
Bui BV; Vingrys AJ; Wellard JW; Kalloniatis M
Eur J Neurosci; 2004 Sep; 20(6):1525-37. PubMed ID: 15355319
[TBL] [Abstract][Full Text] [Related]
12. Influence of probenecid on the delivery of morphine-6-glucuronide to the brain.
Tunblad K; Hammarlund-Udenaes M; Jonsson EN
Eur J Pharm Sci; 2005 Jan; 24(1):49-57. PubMed ID: 15626577
[TBL] [Abstract][Full Text] [Related]
13. PET-evaluated transport of [11C]hydroxyurea across the rat blood-brain barrier--lack of influence of cyclosporin and probenecid.
Syvänen S; Barletta J; Blomquist G; Långström B; Bergström M
Drug Metab Lett; 2007 Aug; 1(3):189-94. PubMed ID: 19356042
[TBL] [Abstract][Full Text] [Related]
14. Effects of probenecid on brain-cerebrospinal fluid-blood distribution kinetics of E-Delta 2-valproic acid in rabbits.
Scism JL; Powers KM; Artru AA; Chambers AC; Lewis L; Adkison KK; Kalhorn TF; Shen DD
Drug Metab Dispos; 1997 Dec; 25(12):1337-46. PubMed ID: 9394022
[TBL] [Abstract][Full Text] [Related]
15. Probenecid, an inhibitor of transmembrane organic anion transporters, alters tissue distribution of DNA adducts in 1-hydroxymethylpyrene-treated rats.
Monien BH; Müller C; Bakhiya N; Donath C; Frank H; Seidel A; Glatt H
Toxicology; 2009 Jul; 262(1):80-5. PubMed ID: 19481134
[TBL] [Abstract][Full Text] [Related]
16. The role of probenecid-sensitive organic acid transport in the pharmacokinetics of N-methyl-D-aspartate receptor antagonists acting at the glycine(B)-site: microdialysis and maximum electroshock seizures studies.
Hesselink MB; Smolders H; Eilbacher B; De Boer AG; Breimer DD; Danysz W
J Pharmacol Exp Ther; 1999 Aug; 290(2):543-50. PubMed ID: 10411561
[TBL] [Abstract][Full Text] [Related]
17. Modelling of the blood-brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport.
Xie R; Bouw MR; Hammarlund-Udenaes M
Br J Pharmacol; 2000 Dec; 131(8):1784-92. PubMed ID: 11139459
[TBL] [Abstract][Full Text] [Related]
18. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.
Jaehde U; Sörgel F; Reiter A; Sigl G; Naber KG; Schunack W
Clin Pharmacol Ther; 1995 Nov; 58(5):532-41. PubMed ID: 7586947
[TBL] [Abstract][Full Text] [Related]
19. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing.
Tan AY; LeVatte TL; Archibald ML; Tremblay F; Kelly ME; Chauhan BC
J Glaucoma; 2002 Apr; 11(2):134-42. PubMed ID: 11912361
[TBL] [Abstract][Full Text] [Related]
20. Probenecid Reduces Alcohol Drinking in Rodents. Is Pannexin1 a Novel Therapeutic Target for Alcohol Use Disorder?
Tunstall BJ; Lorrai I; McConnell SA; Gazo KL; Zallar LJ; de Guglielmo G; Hoang I; Haass-Koffler CL; Repunte-Canonigo V; Koob GF; Vendruscolo LF; Sanna PP
Alcohol Alcohol; 2019 Jan; 54(5):497-502. PubMed ID: 31535696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
